Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA Mounjaro starter bundle is a way of describing the first pen or first supply of tirzepatide, the dual GIP and GLP-1 receptor agonist licensed in the UK for weight management, alongside the clinical support needed to begin treatment safely. Because tirzepatide is a prescription-only medicine, any legitimate starting package must include a prescriber assessment — the pen is one part, not the whole picture. This page explains what a proper starter supply looks like, what the first weeks involve, and how to begin through a regulated route.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The term 'starter bundle' is used loosely online, but clinically there is a defined beginning to tirzepatide treatment: a 2.5 mg pen, which delivers four weekly doses. This is not the dose at which most people experience meaningful weight loss (the tirzepatide overview explains the mechanism in more detail) but it serves a specific purpose. Starting low gives the gut time to adapt to the medicine's effect of slowing gastric emptying and increasing fullness signals. Skipping straight to a higher dose would mean most people experience much stronger nausea and gastrointestinal discomfort than necessary.
A question our prescribers hear most weeks is whether someone can start at 5 mg to 'speed things up'. The short answer, from both the Mounjaro SmPC and NHS guidance on tirzepatide, is that the starting dose is set deliberately, and it is the prescriber's job (not the patient's) to decide when and whether to move up. Any legitimate starter supply will come with that clinical context, not just the pen.
Beyond the pen itself, a proper starter package should include: written information about injection technique (rotation of sites across the abdomen, thigh or upper arm matters from day one), guidance on storing the pen at 2–8°C, and a clear route to aftercare if questions arise in those first weeks. At nume, that aftercare runs seven days a week, and our Mounjaro weight loss app is there to support you through every stage of your treatment. Worth checking those details before you commit to any provider.
No bundle, starter kit or introductory offer changes the eligibility requirements for tirzepatide. The medicine is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition, such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance.
NICE's appraisal of tirzepatide (TA1026) sets tighter criteria for NHS access, but the licensed criteria above apply to private treatment. Either way, BMI alone is never the whole assessment. A prescriber considers your full medical history, current medicines, and any contraindications, including whether pregnancy, breastfeeding or certain gastrointestinal conditions are relevant. Under-18s are not licensed to use this treatment.
The practical implication: if you see a 'starter bundle' advertised with no mention of a prescription or clinical review, that is the first red flag. Tirzepatide is a prescription-only medicine under UK law, and it cannot legally be supplied without one. The Mounjaro starter kit page covers what this looks like in practice.
The first four weeks tend to be a period of adjustment rather than rapid change. Appetite suppression typically builds gradually; most people notice it more clearly by weeks three or four. Gastrointestinal effects (nausea, loose stools, indigestion) are common early on and usually settle as the body adapts. They tend to be more pronounced after injecting and often ease within a few days. Eating smaller meals, avoiding very rich or fatty food, and staying well hydrated all help.
Fatigue and mild headache in the first fortnight are also reported. These are generally short-lived. Serious reactions are uncommon but worth knowing: severe, persistent stomach pain that spreads to the back could indicate pancreatitis and needs prompt medical attention. The MHRA issued a specific Drug Safety Update for GLP-1 medicines on this point in January 2026, and it applies to tirzepatide. Any suspected side effects can be reported at the MHRA's Yellow Card scheme.
After the first pen, your prescriber will review how you have responded before deciding on the next step. That review is not optional, at nume, every repeat supply involves a fresh clinical check. For people thinking about longer multi-pen options, the three-month bundle overview explains how titration across several pens is typically structured. Considering the costs involved, the Mounjaro cost and access page sets out what a transparent, all-inclusive price covers.
The process at a GPhC-registered online pharmacy follows a clear sequence. You complete a free clinical consultation, answering questions about your health, weight and medical history. A GPhC-registered Independent Prescriber reviews your answers personally, the same day. If the medicine is clinically suitable, a prescription is issued and the pen is dispensed from a pharmacy registered with the General Pharmaceutical Council (GPhC premises registration: 9012878). You can verify any online pharmacy on the GPhC register before handing over any payment details.
At nume, the consultation is free, there is no subscription, and every order includes free next-working-day tracked delivery. A real clinician reads your consultation, not an automated triage tool. Identity is verified, weight is confirmed on a live video call, and your GP is notified in line with GPhC guidance. That infrastructure is what separates a clinical starter experience from a transaction. The Mounjaro treatment page covers the full process. When you are ready to take the next step, you can speak to our prescribers through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.